NTRANS TECHNOLOGIES BV

Their core work

NTRANS Technologies is a Leiden-based biotech SME that developed the iTOP (induced transduction by osmocytosis and propanebetaine) kit — a proprietary platform for delivering proteins and other biological molecules directly into living cells without genetic modification. Their core expertise is intracellular delivery technology, which is foundational to cell reprogramming workflows including the generation of induced pluripotent stem cells (iPSCs). Building on this delivery platform, they have expanded into regenerative medicine consortia, contributing their technology to large-scale research on stem cell-based therapies for spinal disc degeneration. They sit at the intersection of cell biology tooling and clinical application, bridging the gap between laboratory reagent development and therapeutic translation.

What they specialise in

How they've shifted over time

In their first project (2017–2019), NTRANS focused entirely on building and commercializing a delivery technology platform — the iTOP kit — with no therapeutic application keywords attached. By their second project (2019–2024), the keywords shift entirely to therapeutic application: induced pluripotent stem cells, biomaterials, spinal disc regeneration, and regenerative medicine. This suggests a deliberate strategic move from tool provider to therapeutic technology contributor, using their delivery expertise as an entry point into clinical-stage consortia. The trajectory points toward NTRANS positioning itself as a cell therapy enablement company rather than a reagent supplier.

NTRANS is moving upstream from research-tool developer toward therapeutic application partner, with their delivery technology serving as the bridge into cell therapy and spinal regeneration programs — a direction that aligns with growing clinical interest in iPSC-based treatments.

How they like to work

NTRANS has demonstrated both independent leadership (winning a competitive SME Phase 2 grant as coordinator) and the ability to integrate into large multi-partner RIA consortia as a specialist contributor. Their participation in iPSpine — a project with 24 partners across 9 countries — suggests they are comfortable operating in complex, multi-institutional environments while providing a focused technological input. They appear to bring a specific, well-defined capability to consortia rather than acting as a generalist partner.

NTRANS has built connections with 24 unique consortium partners across 9 countries, predominantly through the large iPSpine RIA consortium. Their network spans Western and Northern Europe, consistent with their Netherlands base and the typical geography of health and regenerative medicine RIA projects.

What sets them apart

NTRANS holds a rare position as an SME that independently developed and commercialized a proprietary intracellular delivery technology (iTOP), then used that platform as the technical foundation to enter large clinical-research consortia. Most organizations either develop tools or apply them — NTRANS does both, which makes them valuable both as a research reagent supplier and as a consortium technology partner. For anyone working in cell reprogramming, iPSC manufacturing, or ex-vivo cell therapy, their delivery expertise is a direct and differentiated contribution.

Highlights from their portfolio

• ENTRANCE
  A competitive SME Phase 2 solo grant (EUR 1.5M) to develop and commercialize the iTOP intracellular delivery kit — a direct validation of their core technology by EU evaluators.
• iPSpine
  A large RIA consortium (2019–2024, EUR 770K to NTRANS) targeting iPSC-based therapy for intervertebral disc degeneration — demonstrating that NTRANS's delivery platform is relevant at the clinical research frontier.